Key Inclusion Criteria:

          -  Written informed consent provided.

          -  Histologically or cytologically confirmed metastatic uveal melanoma or Metastatic
             NRAS-mutant melanoma .

          -  At least one measurable lesion can be accurately measured per RECIST 1.1 by
             investigator.

          -  ECOG performance status of 0 or 1.

          -  Adequate organ system functions as defined in the protocol

          -  A male subject must agree to use contraception as detailed in protocol during the
             treatment period and through 30 days after the last dose of study treatment and must
             refrain from donating sperm during this period.

          -  A female subject is eligible to participate if she is not pregnant, not breastfeeding.

        Key Exclusion Criteria:

          -  Has had major surgery or significant traumatic injury within 28 days prior to first
             dose of study treatment, or anticipation of the need for major surgery during study
             treatment.

          -  Has received prior systemic anticancer therapy including investigational agents, such
             as within 14 days or less than 5 half-lives (whichever is shorter) of chemotherapy or
             targeted therapy, or within 28 days of immunotherapy, prior to first dose of study
             treatment.

          -  Has received prior radiotherapy within 14 days prior to first dose of study treatment.

          -  Has received prior treatment of any FAK inhibitor (Part 1&2), or prior treatment of
             any MEK inhibitor (Part 2 only).

          -  Has a known previous or concurrent cancer that is distinct in primary site or
             histology from current uveal melanoma within 3 years prior to first dose of study
             treatment, except for curatively treated cancers such as cervical carcinoma in situ).

          -  Has known active central nervous system (CNS) metastases and/or carcinomatous
             meningitis.

          -  Has a history of major cardiovascular, cerebrovascular or thromboembolic diseases
             within 6 months before first dose of study treatment, or has any of the abnormality
             defined in protocol:

          -  Part 2 only: Has history or current evidence of retinal pigmented epithelial
             detachment, central serous retinopathy, or retinal vein occlusion in the unaffected
             eye; or intraocular pressure > 21 mmHg or uncontrolled glaucoma (irrespective of
             intraocular pressure) in the unaffected eye.

          -  Has known uncontrollable pleural effusion, pericardial effusion, or ascites requiring
             repeated drainage prior to the first dose of study treatment.

          -  Has malabsorption syndrome or inability to take oral drugs or Has clinically
             significant gastrointestinal abnormalities.

          -  Known allergy or hypersensitivity to IN10018 and/or cobimetinib, or their ingredients.

          -  Has an active infection requiring systemic therapy within 14 days prior to the first
             dose of study treatment.

          -  Has known HIV/ active HBV/ active HCV infection.

          -  subject is not suitable for participating this study based on the investigator's
             judgement.

          -  has used Strong CYP3A inhibitors/inducers or P-gp inhibitors within 14 days prior to
             first dose of study treatment and during study treatment.